kugerageza kuvura kanseri ya prostate

Kuvura kanseri ya prostate tanga ibyiringiro kubarwayi mugihe ubuvuzi busanzwe butagikora neza. Ubu buvuzi buraboneka kenshi binyuze mubigeragezo byamavuriro, gukora ubushakashatsi muburyo bushya nka immunotherapie, kuvura intego, kuvura gene, hamwe nubuhanga buhanitse bwimirasire. Mugihe hakiri iperereza, ubwo buryo bushobora gutanga inyungu zikomeye kubantu bamwe.Kumva Kanseri ya Prostate no Kuvura Kanseri ya prostate ni indwara yiganje yibasira abagabo kwisi yose. Nubwo ubuvuzi gakondo nko kubaga, kuvura imirasire, hamwe no kuvura imisemburo akenshi bigenda neza, indwara zimwe na zimwe zirwanya, bikenera ubushakashatsi bwa ubushakashatsi bwa kanseri ya prostate.Ubuvuzi bwa Kanseri ya Prostate Mbere yo kubitekerezaho ubushakashatsi bwa kanseri ya prostate, ni ngombwa kumva amahitamo asanzwe. Muri byo harimo: Kubaga (Prostatectomy) Ubuvuzi bwimirasire (Beam External Beam, Brachytherapy) Ubuvuzi bwa Hormone (Androgen Deprivation Therapy) ChimiotherapieIyo Tekereza Kubuvuzi Bwubushakashatsi.Kuvura kanseri ya prostate mubisanzwe bifatwa mugihe ubuvuzi busanzwe bwananiranye cyangwa butagikora neza. Abarwayi bafite kanseri ya prostate yateye imbere cyangwa metastatike barashobora kandi gushakisha ubwo buryo. Ni ngombwa kuganira na oncologue wawe niba kwitabira ikizamini cyamavuriro cyangwa gukurikirana an kugerageza kuvura kanseri ya prostate ni byiza kuri wewe. Ubwoko bwa Kanseri ya Prostate Yipimishije Ubwoko bwa ubushakashatsi bwa kanseri ya prostate ubu barimo gukorwaho iperereza. Muri byo harimo: ImmunotherapyImmunotherapy ikoresha imbaraga zumubiri wumubiri wo kurwanya kanseri. Ingero muri kanseri ya prostate zirimo:Inzitizi za bariyeri: Ibiyobyabwenge nka pembrolizumab na nivolumab birashobora guhagarika poroteyine zibuza ubudahangarwa bw'umubiri kwibasira kanseri.CAR T-selile ivura: Mugihe hakiri kare iterambere rya kanseri ya prostate, CAR T-selile ivura ikubiyemo guhindura T-selile yumurwayi kugirango yibasire kandi isenye kanseri.Inkingo za Kanseri: Izi nkingo zitera ubudahangarwa bw'umubiri kumenya no gutera kanseri ya prostate. Kwihorera (sipuleucel-T) ni urukingo rwemewe, kandi abashakashatsi barimo gutegura ingamba nshya zo gukingira. Inzitizi za PARP: Ibiyobyabwenge nka olaparib na rucaparib byibasira imisemburo ya PARP, bigira uruhare mu gusana ADN. Zifite akamaro muri kanseri ya prostate hamwe na mutation zimwe na zimwe (urugero, BRCA1 / 2).PI3K / AKT / mTOR Inhibitor: Iyi miti igamije inzira yerekana inzira itera kanseri ikura. Barimo gukorwaho iperereza mu mavuriro ya kanseri ya prostate.Imiti ya radiofarmaceuticals: Iyi miti itanga imirasire ya selile. Lutetium-177 PSMA-617 ni radiofarmaceutical yemewe yibasira PSMA (prostate yihariye ya membrane antigen), poroteyine iboneka mu ngirabuzimafatizo za kanseri ya prostate. Abashakashatsi barimo gushakisha uburyo bwo kuvura gene kugira ngo bagere ku ngirabuzimafatizo ya kanseri ya prostate cyangwa bongere ubushobozi bw’umubiri bwo kumenya no gutera kanseri.Ubuvuzi bwa stereotactique yumubiri (SBRT): Gutanga urugero rwinshi rwimirasire kumwanya muto, neza neza.Ubuvuzi bwa Proton: Koresha proton aho gukoresha X-imirasire, ishobora kugabanya kwangirika kwinyama zikikije.Igeragezwa rya Clinical: Inzira yo Kuvura IkigereranyoIgeragezwa rya kliniki ni ubushakashatsi bwubushakashatsi busuzuma ibishya ubushakashatsi bwa kanseri ya prostate. Kugira uruhare mu igeragezwa ry’amavuriro birashobora gutanga uburyo bwo kuvura bigezweho kandi bikagira uruhare mu guteza imbere ubushakashatsi bwa kanseri. Ni ngombwa gusuzuma ibipimo byo gushyiramo / guhezwa, ingaruka zishobora kubaho hamwe nigishushanyo mbonera cyo kwiga. Birasabwa kugisha inama itsinda ryanyu ryita kubuvuzi mbere yo gutekereza kwiyandikisha mu kizamini icyo ari cyo cyose cy’amavuriro. Gushakisha ibizamini bya Clinical Inkomoko yo gushakisha ibizamini by’amavuriro harimo:Ikigo cy'igihugu gishinzwe kanseri (NCI) Gushakisha Ibizamini bya ClinicalAmavuriro.govIbitekerezo by'ingenzi Mbere yo gukurikirana ubushakashatsi bwa kanseri ya prostate, tekereza kuri ibi bikurikira: Gisha inama hamwe na Oncologue wawe Muganire ku buryo bwose bwo kuvura hamwe na oncologue wawe, harimo inyungu n'ingaruka za ubushakashatsi bwa kanseri ya prostate.Gusobanukirwa Ingaruka ninyungu Witondere neza inyungu zishobora kuba za an kugerageza kuvura kanseri ya prostate kurwanya ingaruka zishobora kubaho n'ingaruka mbi. Ubuvuzi bw'igeragezwa bushobora kugira ingaruka zitazwi cyangwa zitateganijwe.Ikiguzi cyubwishingizi hamwe nubwishingizi Reba hamwe nuwaguhaye ubwishingizi kugirango umenye ubwishingizi kuri ubushakashatsi bwa kanseri ya prostate. Ibiciro birashobora gutandukana cyane, kandi imiti imwe nimwe ntishobora gutwikirwa. Twizere ko ejo hazazaKuvura kanseri ya prostate tanga ibyiringiro kubarwayi bananiwe uburyo busanzwe bwo kuvura. Binyuze mu bushakashatsi bukomeje no mu mavuriro, abahanga barimo gutegura uburyo bushya kandi bushya bwo kurwanya iyi ndwara. Shandong Baofa Ikigo Cyubushakashatsi Kanseri yitangiye gushakisha uburyo bwo kuvura kanseri igezweho. Nkikigo cyambere mubushakashatsi bwa kanseri, twiyemeje kuzamura imibereho yabarwayi binyuze mugushiraho ingamba zo kuvura udushya. Gusobanukirwa PSMA-Targeted TherapyPSMA, cyangwa prostate yihariye ya membrane antigen, ni poroteyine iboneka murwego rwo hejuru hejuru ya selile kanseri ya prostate. Ibi bituma iba intego yingirakamaro kuri ubushakashatsi bwa kanseri ya prostate.Ni ubuhe buryo PSMA-igamije kuvura imirimo ya PSMA igamije guhuza cyane cyane na PSMA ku ngirabuzimafatizo za kanseri ya prostate, igatanga imiti ivura ikibyimba. Ubu buryo bugamije kugabanya ibyangiritse kuri selile nzima. Ingero zubuvuzi bwa PSMA Lutetium-177 PSMA-617: Iyi radiofarmaceutical ihuza molekile yibasira PSMA hamwe na radiyo ikora isotope lutetium-177. Itanga imirasire igenewe PSMA yerekana kanseri ya prostate. Reba amakuru hano: FDA.gov PSMA-Ikingira Immunotherapy: Abashakashatsi barimo gukora ubudahangarwa bwibasira PSMA kugirango bakangure ubudahangarwa bw'umubiri kwibasira kanseri ya prostate.Uruhare rwo kwipimisha genetike mu byemezo byo kuvura indwara. ubushakashatsi bwa kanseri ya prostate. Imihindagurikire y’imiterere imwe n'imwe irashobora guhanura uburyo umurwayi yakira neza imiti yihariye, cyane cyane imiti igamije nka PARP inhibitor.Imihindagurikire y’imiterere rusange ya Kanseri ya ProstateBimwe mu ihinduka ry’imiterere ikunze kuboneka muri kanseri ya prostate harimo: BRCA1 na BRCA2: Izi gen zigira uruhare mu gusana ADN. Guhindagurika muri utwo tugingo birashobora gutuma selile ya kanseri ishobora kwanduzwa na PARP inhibitor. ATM: Indi gen igira uruhare mu gusana ADN. Guhinduka muri ATM birashobora kandi kongera ibyiyumvo kuri PARP inhibitor. MSH2, MSH6, MLH1, PMS2: Izi gen zigira uruhare mugusana bidahuye. Guhinduka muri utwo tugingo birashobora gutuma habaho ihungabana rya microsatellite (MSI), rishobora gutuma ingirabuzimafatizo za kanseri zishobora kwanduzwa na immunotherapi. PI3K / AKT / mTOR Inhibitor, Radiopharmaceuticals Yibanda kuri molekile cyangwa inzira zihariye zigira uruhare mu mikurire ya kanseri Indwara zisobanutse neza, zishobora kuba nkeya ugereranije na chimiotherapie Gene Therapy Gutanga ingirabuzima fatizo zirwanya kanseri Kwinjiza indwara mu ngirabuzimafatizo kugira ngo bivure indwara Birashoboka ko umuntu yakira imiti igabanya ubukana bwa tekinike, dosiye irashobora gutangwa